Abiopharma

VERTEX PHARMACEUTICALS INC / MA (VRTX) Announces Business Combination VERTEX PHARMACEUTICALS INC / MA (VRTX) has entered into a strategic transaction. Transaction Details:

• Target Company: crinetics pharmaceuticals
• Purchase Price: $3.33
• Transaction Type: asset
  • Vertex presented new data on ALYFTREK at the European Cystic Fibrosis Conference demonstrating the potentially transformative impact of treating cystic fibrosis with ALYFTREK in children 2 to 5 years of age. The Phase 3 data set shows that 65% of children in the study, including those with F/F and F/MF genotypes, reached carrier sweat chloride levels of <30 mmol/L, with a mean reduction in sweat chloride of
  • 6 mmol/L from a baseline on TRIKAFTA. ALYFTREK was generally safe and well tolerated. Vertex recently initiated global regulatory submissions for this age group.
  • In the second quarter of 2026, Vertex secured reimbursement for ALYFTREK in four additional countries, including Spain, bringing the total number of countries where ALYFTREK is reimbursed to